Hormonal therapies represent the first and most successful targeted therapies in cancer. In most breast and prostate cancers, hormonal therapy forms the very backbone of systemic treatment. However, resistance to therapy is common, and many patients relapse despite treatment.
Our group studies hormonal action in multiple tumor types. Our ultimate goal is to better understand hormonal signaling and elucidate therapy resistance in cancer, contributing to more personalized treatments, the identification of novel therapeutic options and minimizing over-treatment